«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2023 07

Page:

1340-1343

Research Field:

Publishing date:

Info

Title:

Considerations and experiences of the treatment of neuroendocrine neoplasms with integrated traditional Chinese and Western medicine

Author(s):

CHEN Yingying¹; 2; CHENG Zixuan¹; 2; TAN Huangying²

1.Graduate School of Beijing University of Chinese Medicine,Beijing 100029,China£»2.Department of Integrative Oncology,China-Japan Friendship Hospital,Beijing 100029£¬China.

Keywords:

neuroendocrine neoplasms; integrated traditional Chinese and Western medicine; treatments; thoughts

PACS:

R739.4

DOI:

10.3969/j.issn.1672-4992.2023.07.032

Abstract:

Neuroendocrine neoplasms (NENs) are a group of rare tumors that spread throughout the body with strong heterogeneity,but are commonly observed in the digestive tract and pancreas.Among them,well-differentiated neuroendocrine tumors can show relatively good survival prognosis,while some tumors have malignant biological behaviors,resulting in high mortality,and overall efficacy is still unsatisfactory.The author has been focusing on the diagnosis and treatment of neuroendocrine tumors for many years,keeping up with the research frontiers at home and abroad.At the same time,we explored the treatments of integrated traditional Chinese and Western medicine in different sites of neuroendocrine tumors and various entry points such as well-differentiated and poor-differentiated tumors.The author believes that "benefiting qi,strengthening spleen and harmonizing stomach" should be considered throughout the entire process of neuroendocrine tumor treatment.At the same time,it is necessary to pay attention to soothing the liver and regulating qi,emphasizing the "harmonization of the liver and spleen".In addition,treatments according to combination of diseases differentiation and syndromes differentiation can provide patients with individualized treatments£¬which can lead a good clinical effectiveness.

References:

£Û1£Ý³Â½à,ÄôÓÂÕ½,ÎâÎÄÃú,µÈ.ÖйúÖ×ÁöÕûºÏÕïÖÎÖ¸ÄÏ¡¤Éñ¾­ÄÚ·ÖÃÚÖ×Áö£ÛM£Ý.Ìì½ò£ºÌì½ò¿Æѧ¼¼Êõ³ö°æÉç,2022:351-352. CHEN J,NIE YZ,WU WM,et al.CACA guidelines for holistic integrative management of cancer.Neuroendocrine neoplasm£ÛM£Ý.Tianjin:Tianjin Science and Technology Press,2022:351-352.
£Û2£ÝDASARI A,SHEN C,HALPERIN D,et al.Trends in the incidence,prevalence,and survival outcomes in patients with neuroendocrine tumors in the United States £ÛJ£Ý.JAMA Oncol£¬2017£¬3(10):1335-1342.
£Û3£ÝWHO Classification of Tumours Editorial Board.Digestive system tumours(5thed).WHO classification of tumours £ÛM£Ý.Geneva:WHO,2019:16-19.
£Û4£Ýñ¼¶¹,ÇñÐñ¶«,³ÂÓ¨Ó¨,µÈ.¡°ÊèľÁù¾ý×ÓÌÀ¡±¼Ó¼õÖÎÁÆ1ÐÍθÉñ¾­ÄÚ·ÖÃÚÖ×ÁöµÄÁÙ´²¹Û²ì£ÛJ£Ý.ÁÙ´²Ö×ÁöѧÔÓÖ¾,2019,24(09):824-827. DOU D,QIU XD,CHEN YY,et al.The clinical observation of modified ShumuLiujunzi Decoction for type 1 gastric neuroendocrine neoplasm£ÛJ£Ý.Chinese Clinical Oncology,2019,24(09):824-827.
£Û5£ÝÕÅÅÎ.ÖÐÒ©Ô¤·À¸ß·Ö»¯ÒÈÏÙÉñ¾­ÄÚ·ÖÃÚÖ×Áö¸ùÖÎÊõºó¸´·¢µÄÁÙ´²Ñо¿£ÛD£Ý.±±¾©ÖÐÒ½Ò©´óѧ,2017. ZHANG P.Clinical study of traditional Chinese medicine in preventing recurrence of well-differentiated pancreatic neuroendocrine tumor after radical resection£ÛD£Ý.Beijing University of Chinese Medicine,2017.
£Û6£ÝÀî÷,ñ¼¶¹,ÂÞ½Ü,µÈ.ÖÐÒ©ÁªºÏÉú³¤ÒÖËØÀàËÆÎïÖÎÁÆÍíÆÚ賦ÒÈÏÙÉñ¾­ÄÚ·ÖÃÚÖ×ÁöµÄÁÆЧ·ÖÎö£ÛJ£Ý.ÁÙ´²Ö×ÁöѧÔÓÖ¾,2017,22(03):238-242. LI M,DOU D,LUO J,et al.Clinical observation on traditional Chinese medicine in combination with somatostatin analogues for advanced gastroenteropancreatic neuroendocrine tumors£ÛJ£Ý.Chinese Clinical Oncology,2017,22(03):238-242.
£Û7£Ý½¹ÅàÅà,ÆîÖ¾ÈÙ,ÀîÔ¶Á¼,µÈ.Éú³¤ÒÖËØÀàËÆÎïÅäºÏÖÐÒ©ÖÎÁÆ68ÀýÍíÆÚ賦ÒÈÉñ¾­ÄÚ·ÖÃÚÖ×ÁöµÄÁÆЧ¹Û²ì£ÛJ£Ý.ÖÐÈÕÓѺÃҽԺѧ±¨,2022,36(02):92-94. JIAO PP,QI ZR,LI YL,et al.Clinical observation on somatostatin analogues in combination with traditional Chinese medicine for 68 patients with advanced gastroenteropancreatic neuroendocrine tumors£ÛJ£Ý.Journal of China-Japan Friendship Hospital,2022,36(02):92-94.
£Û8£ÝDELLE FG,O' TOOLE D,SUNDIN A,et al.ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms £ÛJ£Ý.Neuroendocrinology,2016,103(2):119-124.
£Û9£ÝESPOSITO G,CAZZATO M,RINZIVILLO M,et al.Management of type-I gastric neuroendocrine neoplasms:A 10-years prospective single centre study £ÛJ£Ý.Dig Liver Dis,2021,54(7):890-895.
£Û10£ÝROSSI RE,INVERNIZZI P,MAZZAFERRO V,et al.Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids:A systematic review and meta-analysis £ÛJ£Ý.United European Gastroenterol J,2020,8(2):140-147.
£Û11£ÝÀîÔ¶Á¼,Ì·»ÍÓ¢.Éú³¤ÒÖËØÀàËÆÎïÔÚ1ÐÍθÉñ¾­ÄÚ·ÖÃÚÖ×ÁöÖеÄÖÎÁƽøÕ¹£ÛJ£Ý.ÖÐÈÕÓѺÃҽԺѧ±¨,2017,31(03):187-189. LI YL,TAN HY.Advances in the treatment of somatostatin analogues in type 1 gastric neuroendocrine tumors£ÛJ£Ý.Journal of China-Japan Friendship Hospital,2017,31(03):187-189.
£Û12£ÝIDA H,HONMA Y,HIRANO H,et al.Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs:a retrospective study£ÛJ£Ý.Invest New Drugs,2019,37(3):573-578.
£Û13£ÝBORBATH I,PAPE UF,DEPREZ PH,et al.ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors£ÛJ£Ý.J Neuroendocrinol,2022,34(3):e13105.
£Û14£Ý³ÂÓ¨Ó¨.ÖÐÒ©¡°ÊèľÁù¾ý×ÓÌÀ¡±¼Ó¼õÖÎÁÆ1ÐÍθÉñ¾­ÄÚ·ÖÃÚÖ×ÁöµÄÁÙ´²¶ÔÕÕ¹Û²ì£ÛD£Ý.±±¾©ÖÐÒ½Ò©´óѧ,2020. CHEN YY.A clinical controlled observation of Chinese Herbal Decoction (ShumuLiujunzi) for type 1 gastric neuroendocrine tumors£ÛD£Ý.Beijing University of Chinese Medicine,2020.
£Û15£ÝCHEN YY,HAN D,ZHU JQ,et al.A prospective and retrospective clinical controlled observation of Chinese herbal decoction (SMLJ01) for type 1 gastric neuroendocrine tumors £ÛJ£Ý.Integr Cancer Ther,2020,19:1534735420958488.
£Û16£ÝNOH JH,KIM DH,YOON H,et al.Clinical outcomes of endoscopic treatment for type 1 gastric neuroendocrine tumor£ÛJ£Ý.J Gastrointest Surg,2021,25(10):2495-2502.
£Û17£Ýº«µÇ,ÀîÔ¶Á¼,³ÂÓ¨Ó¨,µÈ.dz̸̷»ÍÓ¢½ÌÊÚÖÐÎ÷Ò½½áºÏÖÎÁÆ1ÐÍθÉñ¾­ÄÚ·ÖÃÚÖ×ÁöµÄÁÙ´²¾­Ñé£ÛJ£Ý.°©Ö¢½øÕ¹,2021,19(19):1961-1963. HAN D,LI YL,CHEN YY,et al.A brief discussion about the clinical experience of Professor Tan Huangying in the treatment of type 1 gastric neuroendocrine tumor with integrated traditional Chinese and Western medicine£ÛJ£Ý.Oncology Progress,2021,19(19):1961-1963.
£Û18£Ý³ÂÓ¨Ó¨,ñ¼¶¹,Ì·»ÍÓ¢.ÏãÉ°Áù¾ý×ÓÌÀ¼Ó¼õÖÎÁÆ1ÐÍθÉñ¾­ÄÚ·ÖÃÚÖ×Áö£ÛJ£Ý.¹âÃ÷ÖÐÒ½,2017,32(22):3318-3320. CHEN YY,DOU D,TAN HY.Treatment for type 1 gastric neuroendocrine tumor with Xiangsha Liujunzi Decoction£ÛJ£Ý.Guangming Journal of Chinese Medicine,2017,32(22):3318-3320.
£Û19£ÝFAN JH,ZHANG YQ,SHI SS,et al.A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in China £ÛJ£Ý.Oncotarget,2017,8(42):71699-71708.
£Û20£ÝHAN IW,PARK J,PARK EY,et al.Fate of surgical patients with small nonfunctioning pancreatic neuroendocrine tumors:An international study using multi-institutional registries£ÛJ£Ý.Cancers (Basel),2022,14(4):1038.
£Û21£ÝSINGH S,CHAN DL,MOODY L,et al.Recurrence in resected gastroenteropancreatic neuroendocrine tumors£ÛJ£Ý.JAMA Oncol,2018,4(4):583-585.
£Û22£ÝROSENBLUM RE,HARRIS CK,BAEG KJ,et al.Predictors of recurrence and survival in patients with surgically resected pancreatic neuroendocrine tumors£ÛJ£Ý.Pancreas,2020,49(2):249-254.
£Û23£ÝBARRETT JR,RENDELL V,POKRZYWA C,et al.Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit £ÛJ£Ý.J Surg Oncol,2020,121(7):1067-1073.
£Û24£ÝÖйúÁÙ´²Ö×Áöѧ»áÖ¸ÄϹ¤×÷ίԱ»á.ÖйúÁÙ´²Ö×Áöѧ»á£¨CSCO£©Éñ¾­ÄÚ·ÖÃÚÖ×ÁöÕïÁÆÖ¸ÄÏ£ÛM£Ý.±±¾©:ÈËÃñÎÀÉú³ö°æÉç,2021:74-75. Chinese Society of Clinical Oncology Guidelines Working Committee.Guidelines of Chinese Society of Clinical Oncology (CSCO) neuroendocrine neoplasms£ÛM£Ý.Beijing:People's Medical Publishing House,2021:74-75.
£Û25£ÝÍõöÎ.ÖÐÒ©ÓÃÓڸ߷ֻ¯ÒÈÏÙÉñ¾­ÄÚ·ÖÃÚÖ×Áö¸ùÖÎÊõºó¸¨ÖúÖÎÁƵÄÁÙ´²Ñо¿£ÛD£Ý.±±¾©ÖÐÒ½Ò©´óѧ,2020. WANG X.Clinical study of traditional Chinese medicine for adjuvant therapy after radical resection of well-differentiated pancreatic neuroendocrine tumors£ÛD£Ý.Beijing University of Chinese Medicine,2020.
£Û26£ÝÖлªÒ½Ñ§»áÏû»¯²¡Ñ§·Ö»á賦¼¤ËØÓëÉñ¾­ÄÚ·ÖÃÚÖ×Áöѧ×é.賦ÒÈÉñ¾­ÄÚ·ÖÃÚÖ×ÁöÕïÖÎר¼Ò¹²Ê¶(2020¡¤¹ãÖÝ)£ÛJ£Ý.ÖлªÏû»¯ÔÓÖ¾,2021,41(02):76-87. Gastrointestinal Hormone and Neuroendocrine Neoplasm Group,Chinese Society of Gastroenterology,Chinese Medical Association.Expert consensus on diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasm(2020,Guangzhou)£ÛJ£Ý.Chinese Journal of Digestion,2021,41(02):76-87.
£Û27£ÝMAO R,LI K,CAI JQ,et al.Adjuvant chemotherapy versus observation following resection for patients with nonmetastatic poorly differentiated colorectal neuroendocrine carcinomas £ÛJ£Ý.Ann Surg,2021,274(2):e126-e133.
£Û28£ÝPELLAT A,WALTER T,AUGUSTIN J,et al.Chemotherapy in resected neuroendocrine carcinomas of the digestive tract:A national study from the French Group of Endocrine Tumours£ÛJ£Ý.Neuroendocrinology,2020,110(5):404-412.
£Û29£ÝMOLLAZADEGAN K,WELIN S,CRONA J.Systemic treatment of gastroenteropancreatic neuroendocrine carcinoma£ÛJ£Ý.Curr Treat Options Oncol,2021,22(8):68.
£Û30£ÝPAVEL M,¦ZBERG K,FALCONI M,et al.Gastroenteropancreatic neuroendocrine neoplasms:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up£ÛJ£Ý.Ann Oncol,2020,31(7):844-860.

Memo

Memo:

¹ú¼ÒÎÀÉú½¡¿µÎ¯²ÆÕþרÏî»ù½ðÖ§³Ö×ÊÖú£¨±àºÅ£º2022-NHLHCRF-LX-02-0110£©

Common functions

Last Update: 2023-02-28